Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (226,539)	$ (247,116)	$ (184,062)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,655	1,437	777
Inventory obsolescence	422	932	0
Stock-based compensation expense	55,615	44,701	34,640
Non-cash interest expense on royalty financing obligations and secured term loan and amortization of debt issuance costs	85,803	98,918	54,204
Amortization of premium/discount on investments	(10,263)	(1,777)	(2)
Loss (gain) on extinguishment of debt	29,019	0	(55,838)
Loss on impairment	1,548	0	0
Changes in operating assets and liabilities:
Receivables	(6,095)	(21,470)	(20,817)
Inventory	(1,450)	(12,423)	(8,767)
Prepaid expenses and other assets	(6,820)	(2,583)	(7,155)
Accounts payable and accrued expenses	(16,806)	(22,360)	39,412
Interest payable	0	0	4,168
Deferred revenue	(1,230)	(109)	1,283
Net cash used in operating activities	(95,141)	(161,850)	(142,157)
Cash flows from investing activities:
Acquisitions of property and equipment	(2,168)	(1,351)	(2,385)
Purchases of investments	(514,407)	(244,283)	(10,012)
Sales and maturities of investments	385,077	117,396	28,201
Net cash (used in) provided by investing activities	(131,498)	(128,238)	15,804
Cash flows from financing activities:
Sale of common stock, net	0	0	50,000
Net proceeds from common stock issued under stock-based compensation plans	8,340	14,765	15,734
Net proceeds from common stock issued to directors in lieu of cash retainer	342	190	60
Withholding taxes paid on stock-based awards	(2,172)	0	0
Net proceeds from secured term loans	300,000	73,072	0
Repayment of Athyrium secured term loans principal	(240,452)	0	0
Prepayment and repayment fees on Athyrium secured term loans	(21,261)	0	0
Payment of debt issuance costs on Pharmakon Tranche A term loan	(11,147)	0	0
Principal payments on finance lease liabilities	(1,165)	0	0
Net proceeds from royalty financing liabilities	0	0	293,874
Net cash provided by financing activities	32,485	88,027	359,668
Effects of exchange rates on cash, cash equivalents and restricted cash	362	566	71
(Decrease) increase in cash, cash equivalents and restricted cash	(193,792)	(201,495)	233,386
Cash, cash equivalents and restricted cash at beginning of year	306,239	507,734	274,348
Cash, cash equivalents and restricted cash at end of year	112,447	306,239	507,734
Supplemental cash flow disclosure:
Cash paid for interest	22,139	0	900
Cash paid for taxes	1,434	3,542	118
Taxes withheld on stock-based awards included in accrued expenses	$ 4,199	$ 1,990	$ 984